metformin has been researched along with Carcinoma, Endometrioid in 18 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Carcinoma, Endometrioid: An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin has been demonstrated to play an anti-cancer role in multiple cancers including EC." | 6.82 | The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer. ( Chen, XJ; Guan, J, 2022) |
| "Our findings revealed that metformin could induce endometrial atrophy in 21 out of 22 patients (95." | 5.19 | Antiproliferative effect of metformin on the endometrium--a clinical trial. ( Bidadi, S; Foroughi, M; Ghojazadeh, M; Melli, MS; Tabrizi, AD, 2014) |
| "Metformin has been demonstrated to play an anti-cancer role in multiple cancers including EC." | 2.82 | The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer. ( Chen, XJ; Guan, J, 2022) |
| "Metformin treatment (median 20 days, range 7-34) was associated with a 17." | 2.82 | Measuring the biological effect of presurgical metformin treatment in endometrial cancer. ( Ali, S; Crosbie, EJ; Gilmour, K; Kitchener, HC; Kitson, S; McVey, R; Pemberton, P; Renehan, AG; Roberts, C; Sivalingam, VN, 2016) |
| "Because endometrial cancer is associated with insulin resistance, the authors investigated whether a diabetes-therapeutic metformin dose inhibits cancer cell growth in patients with endometrial cancer." | 2.79 | Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial. ( Kiyokawa, T; Mitsuhashi, A; Sato, Y; Shozu, M, 2014) |
| "Endometrial carcinoma is the common malignant tumor of the female genital tract, and its incidence is increasing." | 2.48 | Endometrial carcinoma tumorigenesis and pharmacotherapy research. ( Fang, S; Huang, H; Shu, J; Teichman, PG; Xing, L, 2012) |
| " This study sought to identify a predictive and/or pharmacodynamic proteomic signature of metformin response to tailor its pharmacologic use." | 1.56 | Jupiter microtubule-associated homolog 1 (JPT1): A predictive and pharmacodynamic biomarker of metformin response in endometrial cancers. ( Ao, W; Bae-Jump, V; Bateman, NW; Casablanca, Y; Conrads, KA; Conrads, TP; Darcy, KM; Hamilton, CA; Hood, BL; Hope, E; Litzy, T; Maxwell, GL; Oliver, J; Teng, PN; Tommarello, D; Wang, G; Wilson, K; Zhou, M, 2020) |
| "This association is less clear in epithelial ovarian cancer (EOC)." | 1.40 | Diabetes mellitus and ovarian cancer: more complex than just increasing risk. ( Daily, LB; Erickson, BK; Fauci, JM; Haygood, CW; Leath, CA; Martin, JY; Matin, T; McGwin, G; Pasko, D; Shah, MM, 2014) |
| "Metformin plays an important role in the inhibition of cancer cell growth and prolongs remission durations." | 1.38 | Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression. ( Dong, L; Duan, T; Feng, Y; Zhang, Z; Zhou, Q; Zhu, Y, 2012) |
| "The proliferation variety of endometrial cancer cells was determined by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium (MTT) assay after exposure to medroxyprogesterone acetate, metformin, or both reagents; apoptosis rates were assessed by flow cytometry." | 1.37 | Metformin reverses progestin resistance in endometrial cancer cells by downregulating GloI expression. ( Dong, L; Feng, Y; Liu, X; Sui, L; Yang, Y; Yu, Y; Zhang, Z; Zhu, Y, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (77.78) | 24.3611 |
| 2020's | 4 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Guan, J | 3 |
| Chen, XJ | 3 |
| Ushijima, K | 1 |
| Tsuda, N | 1 |
| Yamagami, W | 1 |
| Mitsuhashi, A | 2 |
| Mikami, M | 1 |
| Yaegashi, N | 1 |
| Enomoto, T | 1 |
| Soliman, PT | 2 |
| Westin, SN | 2 |
| Iglesias, DA | 1 |
| Fellman, BM | 1 |
| Yuan, Y | 1 |
| Zhang, Q | 2 |
| Yates, MS | 1 |
| Broaddus, RR | 2 |
| Slomovitz, BM | 1 |
| Lu, KH | 2 |
| Coleman, RL | 1 |
| Bateman, NW | 1 |
| Teng, PN | 1 |
| Hope, E | 1 |
| Hood, BL | 1 |
| Oliver, J | 1 |
| Ao, W | 1 |
| Zhou, M | 1 |
| Wang, G | 1 |
| Tommarello, D | 1 |
| Wilson, K | 1 |
| Litzy, T | 1 |
| Conrads, KA | 1 |
| Hamilton, CA | 1 |
| Darcy, KM | 1 |
| Casablanca, Y | 1 |
| Maxwell, GL | 1 |
| Bae-Jump, V | 1 |
| Conrads, TP | 1 |
| Arima, R | 1 |
| Marttila, M | 1 |
| Hautakoski, A | 1 |
| Arffman, M | 1 |
| Sund, R | 1 |
| Ilanne-Parikka, P | 1 |
| Kangaskokko, J | 1 |
| Läärä, E | 1 |
| Puistola, U | 1 |
| Hinkula, M | 1 |
| Kiyokawa, T | 1 |
| Sato, Y | 1 |
| Shozu, M | 1 |
| Shah, MM | 1 |
| Erickson, BK | 1 |
| Matin, T | 1 |
| McGwin, G | 1 |
| Martin, JY | 1 |
| Daily, LB | 1 |
| Pasko, D | 1 |
| Haygood, CW | 1 |
| Fauci, JM | 1 |
| Leath, CA | 1 |
| Tabrizi, AD | 1 |
| Melli, MS | 1 |
| Foroughi, M | 1 |
| Ghojazadeh, M | 1 |
| Bidadi, S | 1 |
| Schrauwen, S | 1 |
| Coenegrachts, L | 1 |
| Cattaneo, A | 1 |
| Hermans, E | 1 |
| Lambrechts, D | 1 |
| Amant, F | 1 |
| Sivalingam, VN | 1 |
| Kitson, S | 1 |
| McVey, R | 1 |
| Roberts, C | 1 |
| Pemberton, P | 1 |
| Gilmour, K | 1 |
| Ali, S | 1 |
| Renehan, AG | 1 |
| Kitchener, HC | 1 |
| Crosbie, EJ | 1 |
| Iglesias, D | 1 |
| Munsell, MF | 1 |
| Schmandt, R | 1 |
| Yates, M | 1 |
| Ramondetta, L | 1 |
| Zhang, Z | 3 |
| Dong, L | 3 |
| Sui, L | 1 |
| Yang, Y | 2 |
| Liu, X | 1 |
| Yu, Y | 1 |
| Zhu, Y | 3 |
| Feng, Y | 3 |
| Mu, N | 1 |
| Wang, Y | 1 |
| Xue, F | 1 |
| Zhou, Q | 2 |
| Duan, T | 2 |
| Shu, J | 1 |
| Fang, S | 1 |
| Teichman, PG | 1 |
| Xing, L | 1 |
| Huang, H | 1 |
| Campagnoli, C | 1 |
| Abbà, C | 1 |
| Ambroggio, S | 1 |
| Brucato, T | 1 |
| Pasanisi, P | 1 |
| Li, W | 1 |
| Yan, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Preoperative Window Study of Metformin for the Treatment of Endometrial Cancer[NCT01911247] | Early Phase 1 | 28 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| A Multi-center, Prospective, Cohort Study to Elucidate the Effects of Metformin Treatment on Steroid Hormones and Social Behavior. Linking Autistic Behaviorial Symptoms to Changes in Steroid Hormone Availability[NCT04930471] | 45 participants (Anticipated) | Observational | 2021-06-30 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for metformin and Carcinoma, Endometrioid
| Article | Year |
|---|---|
The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer.
Topics: Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservat | 2022 |
The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer.
Topics: Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservat | 2022 |
The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer.
Topics: Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservat | 2022 |
The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer.
Topics: Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservat | 2022 |
The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer.
Topics: Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservat | 2022 |
The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer.
Topics: Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservat | 2022 |
The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer.
Topics: Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservat | 2022 |
The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer.
Topics: Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservat | 2022 |
The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer.
Topics: Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservat | 2022 |
Endometrial carcinoma tumorigenesis and pharmacotherapy research.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Carcinoma, Endom | 2012 |
Life-style and metformin for the prevention of endometrial pathology in postmenopausal women.
Topics: Anticarcinogenic Agents; Carcinoma, Endometrioid; Endometrial Neoplasms; Endometrium; Evidence-Based | 2013 |
3 trials available for metformin and Carcinoma, Endometrioid
| Article | Year |
|---|---|
Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial.
Topics: Adult; Aged; AMP-Activated Protein Kinases; Antigens, Neoplasm; Antineoplastic Agents; Blotting, Wes | 2014 |
Antiproliferative effect of metformin on the endometrium--a clinical trial.
Topics: Adult; Antineoplastic Agents, Hormonal; Atrophy; Carcinoma, Endometrioid; Endometrial Hyperplasia; E | 2014 |
Measuring the biological effect of presurgical metformin treatment in endometrial cancer.
Topics: Aged; Aged, 80 and over; Blood Glucose; C-Peptide; Carcinoma, Endometrioid; Endometrial Hyperplasia; | 2016 |
12 other studies available for metformin and Carcinoma, Endometrioid
| Article | Year |
|---|---|
Trends and characteristics of fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer in Japan: a survey by the Gynecologic Oncology Committee of the Japan Society of Obstetrics and Gynecology.
Topics: Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservat | 2023 |
Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Everolimus; Fe | 2020 |
Jupiter microtubule-associated homolog 1 (JPT1): A predictive and pharmacodynamic biomarker of metformin response in endometrial cancers.
Topics: Adolescent; Adult; Aged; Biomarkers, Tumor; Carcinoma, Endometrioid; Cell Cycle Proteins; Cell Line, | 2020 |
Antidiabetic medication, statins and the risk of endometrioid endometrial cancer in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Endometrioid; Case-Control Studies; Diabetes Mellitus, Ty | 2017 |
Diabetes mellitus and ovarian cancer: more complex than just increasing risk.
Topics: Adenocarcinoma, Papillary; Aged; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Comorbidity | 2014 |
The antitumor effect of metformin with and without carboplatin on primary endometrioid endometrial carcinoma in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Endom | 2015 |
Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study.
Topics: Adult; Aged; AMP-Activated Protein Kinases; Apoptosis; Biomarkers, Tumor; Carcinoma, Endometrioid; C | 2016 |
Metformin reverses progestin resistance in endometrial cancer cells by downregulating GloI expression.
Topics: Apoptosis; Carcinoma, Endometrioid; Down-Regulation; Drug Resistance, Neoplasm; Endometrial Neoplasm | 2011 |
Metformin: a potential novel endometrial cancer therapy.
Topics: Carcinoma, Endometrioid; Drug Resistance, Neoplasm; Endometrial Neoplasms; Enzyme Inhibitors; Female | 2012 |
Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression.
Topics: Antineoplastic Agents; Carcinoma, Endometrioid; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dru | 2012 |
Comment on 'Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression'.
Topics: Carcinoma, Endometrioid; Endometrial Neoplasms; Female; Humans; Hypoglycemic Agents; Lactoylglutathi | 2013 |
Response to 'Comment on Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression'.
Topics: Carcinoma, Endometrioid; Endometrial Neoplasms; Female; Humans; Hypoglycemic Agents; Lactoylglutathi | 2013 |